Form 6-K JBS N.V. For: Jun 15

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or

15d-16 of the Securities Exchange Act of 1934

 

For the month of June 2026

 

Commission File Number: 001-42678

 

 

JBS N.V.

(Exact Name as Specified in its Charter)

 

N/A

(Translation of registrant’s name into English)

 

Stroombaan 16, 5th Floor

1181 VX, Amstelveen, Netherlands

(Address of principal executive offices)

 

(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)

 

Form 20-F:   ☒     Form 40-F:   ☐

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On June 15, 2026, JBS N.V. (the “Company”) posted an investor presentation in the “Presentations” tab of the “Results and Presentations” section of the Company’s website at https://ir.jbsglobal.com. The investor presentation will be used by the Company from time to time at investor conferences and in meetings with investors and others beginning on June 15, 2026. The content of the Company’s website is not incorporated by reference herein and is not a part of this Current Report on Form 6-K nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such filing.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: June 15, 2026

 

	JBS N.V.
	By:	/s/ Guilherme Perboyre Cavalcanti
	Name:	Guilherme Perboyre Cavalcanti
	Title:	Global CFO and Investor Relations Officer

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
• Aether AI Raises $20 Million Seed Round to Build Causal World Models for the Next Era of AI
• Small Florida Fence Firm Achieves Record breaking growth by specializing in Premium Residential & Commercial Projects